The MPO-ANCA antibody test detects autoantibodies directed against myeloperoxidase, an enzyme inside neutrophils. A positive result is most strongly associated with microscopic polyangiitis and renal-limited pauci-immune glomerulonephritis. It also occurs in a minority of people with eosinophilic granulomatosis with polyangiitis and in some drug-induced, infectious, autoimmune, or inflammatory conditions. The result cannot diagnose vasculitis without a compatible organ pattern. Its meaning rises sharply when it accompanies glomerular blood and casts in urine, falling kidney function, pulmonary capillaritis, palpable purpura, or mononeuritis multiplex. By contrast, an isolated low-positive result found during broad screening may have limited predictive value. Laboratory units and cutoffs differ, and changes in antibody level are not reliable enough to direct treatment alone. Clinical findings, organ tests, imaging, and biopsy determine whether active vasculitis is present and how urgently it must be treated.
- MPO-ANCA is an antigen-specific antibody, not simply another name for p-ANCA.
- A positive result supports MPA most strongly when kidney, lung, skin, or nerve findings fit.
- Only about a minority of EGPA patients are MPO-ANCA positive; a negative test does not exclude EGPA.
- Drug exposure and chronic infection must be considered before immunosuppression.
- Urine, creatinine, oxygen status, imaging, and biopsy measure organ danger more directly than the titer.
Table of Contents
- What MPO-ANCA Is and How It Is Measured
- What a Positive Result Means
- MPO-ANCA in Microscopic Polyangiitis
- MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis
- Non-Vasculitic and Drug-Related Positives
- Negative, Borderline, and Changing Results
- Next Tests and Urgent Warning Signs
What MPO-ANCA Is and How It Is Measured
Myeloperoxidase is a protein stored in azurophilic granules inside neutrophils and monocytes. These white blood cells use it as part of their antimicrobial system. In MPO-ANCA-associated disease, autoantibodies recognize myeloperoxidase and can participate in abnormal neutrophil activation, endothelial injury, complement-amplified inflammation, and small-vessel damage.
Modern laboratories usually measure MPO-ANCA with an antigen-specific immunoassay. The sample is incubated with purified or recombinant myeloperoxidase, and the assay measures antibody binding. Results may be reported as units per milliliter, international units, an antibody index, or another manufacturer-specific unit.
This creates an important rule: numeric results from different laboratories are not directly interchangeable. A value of 20 may be strongly positive on one platform and negative on another. Interpretation must use the method and reference interval printed on that report.
Some laboratories also perform indirect immunofluorescence on ethanol-fixed neutrophils. MPO antibodies often produce a perinuclear pattern called p-ANCA because positively stained material appears concentrated around the nucleus. The pattern and antigen are related but not equivalent. A p-ANCA result can be caused by antibodies to other neutrophil proteins, particularly in inflammatory bowel disease and autoimmune liver disease. Conversely, an MPO immunoassay identifies the specific target.
Current diagnostic approaches generally prioritize high-quality MPO- and PR3-specific immunoassays when ANCA-associated vasculitis is suspected. Immunofluorescence may be added when the antigen tests are negative despite strong clinical concern, when results are weak or discordant, or when the laboratory uses a reflex algorithm.
No fasting is required. Exercise, a meal, or time of day does not usually determine positivity. The clinically important timing issue is immunosuppressive treatment: corticosteroids, rituximab, cyclophosphamide, and other therapies can lower antibody concentrations over time. Whenever safe, a baseline specimen is collected before treatment, but care should never be delayed in a life-threatening pulmonary-kidney syndrome merely to preserve an untreated test result.
Biotin and routine supplements are not established universal causes of MPO-ANCA interference, but patients should still give the laboratory and clinician a complete medication and supplement list. When a result is unexpected, the laboratory can advise whether the specific assay has known interference or whether dilution, repeat testing, or an alternative platform is appropriate.
What a Positive Result Means
A positive MPO-ANCA result means the assay detected antibodies that bind myeloperoxidase above its validated cutoff. It increases the probability of ANCA-associated vasculitis, but the size of that increase depends on the reason for testing.
Diagnostic probability is highest when objective manifestations are already present, such as:
- Microscopic hematuria with dysmorphic red cells or red blood cell casts
- Rising creatinine or declining eGFR from glomerulonephritis
- Diffuse alveolar hemorrhage or pulmonary capillaritis
- Palpable purpura with small-vessel vasculitis on biopsy
- Mononeuritis multiplex causing asymmetric weakness or sensory loss
- Asthma and marked eosinophilia with systemic vasculitic manifestations
A positive result carries much less weight when testing was ordered for fatigue, diffuse pain, a nonspecific rash, or an elevated ESR without organ evidence. In low-pretest-probability settings, false or clinically irrelevant positives make up a larger fraction of results.
The strength of positivity matters but does not create certainty. A clearly high antibody concentration is generally more persuasive than a borderline result, particularly when repeated on a specific assay. Even a very high value can occur in drug-induced disease or occasionally infection. Conversely, active biopsy-proven vasculitis can be associated with a modest value.
The result does not identify the exact disease by itself. MPO-ANCA occurs most often in MPA, but it can be found in EGPA, GPA, renal-limited vasculitis, and drug-induced syndromes. Classification depends on the phenotype. Asthma, nasal polyps, and eosinophilia point toward EGPA; granulomatous destructive upper-airway disease and cavitating nodules point toward GPA; glomerulonephritis and capillaritis without granulomatous features favor MPA.
MPO-ANCA also does not indicate which organ is currently inflamed. The same antibody result can accompany kidney-limited disease, lung fibrosis, peripheral neuropathy, skin vasculitis, or no active vasculitis. Organ-specific tests establish severity.
The positive predictive value changes with the population being tested. In a nephrology service evaluating rapidly progressive glomerulonephritis, a clear MPO result is highly actionable. In a general screening population, most positives may not represent ANCA-associated vasculitis. This is why laboratories sometimes advise that ANCA be ordered only when defined clinical features are present. Broad testing can identify low-level antibodies that would never have caused symptoms and can lead to unnecessary imaging, biopsy, anxiety, or immunosuppression.
A useful report interpretation should therefore state both the assay result and the phenotype. “MPO-ANCA positive with active glomerular sediment and rising creatinine” conveys a very different probability from “MPO-ANCA weakly positive with normal urine and no vasculitic symptoms.” The antibody never travels alone in clinical decision-making.
MPO-ANCA in Microscopic Polyangiitis
Microscopic polyangiitis is the condition most closely linked to MPO-ANCA. It causes necrotizing inflammation of small vessels, commonly affecting glomeruli and pulmonary capillaries. Granulomatous inflammation is not a defining feature.
Kidney involvement may begin silently. Urinalysis can reveal blood and protein before swelling, nausea, reduced urine output, or other symptoms appear. Urine microscopy showing dysmorphic red blood cells or casts is particularly concerning. Creatinine and eGFR show filtration loss, while a urine protein-to-creatinine ratio quantifies protein leakage.
The characteristic kidney biopsy lesion is pauci-immune necrotizing and crescentic glomerulonephritis. “Pauci-immune” means there are few immune deposits on immunofluorescence, unlike lupus nephritis, IgA nephropathy, or infection-related glomerulonephritis. Biopsy confirms the injury pattern and measures active inflammation versus chronic scarring.
Pulmonary involvement may present as diffuse alveolar hemorrhage. Warning findings include breathlessness, falling oxygen, new bilateral opacities, and a decreasing hemoglobin level. Coughing blood may occur but can be absent. MPO-ANCA disease is also associated with interstitial lung disease; fibrosis can precede vasculitis, accompany it, or progress on a partly separate course.
Other MPA manifestations include palpable purpura, muscle and joint pain, fever, weight loss, abdominal ischemic symptoms, and peripheral nerve injury. Foot drop, wrist drop, or painful asymmetric numbness can reflect mononeuritis multiplex and warrants prompt assessment.
A positive MPO-ANCA plus this clinical pattern may justify starting treatment before biopsy results are available when kidney or lung function is deteriorating rapidly. Biopsy should still be obtained when feasible because infection, anti-GBM disease, and immune-complex glomerulonephritis can require different treatment and carry different prognoses.
The MPA blood test panel therefore extends far beyond the antibody. Creatinine, eGFR, urine sediment, protein quantification, blood count, inflammatory markers, anti-GBM antibody, complement, and chest evaluation determine urgency.
MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis
Eosinophilic granulomatosis with polyangiitis is a distinct disease characterized by adult-onset or worsening asthma, eosinophilia, and systemic inflammation that can involve nerves, lungs, sinuses, skin, heart, kidneys, and the gastrointestinal tract. Only roughly one third of patients are MPO-ANCA positive, although rates vary by cohort and test method.
MPO-positive and ANCA-negative EGPA overlap but tend to show different patterns at the group level. MPO-positive disease is more often associated with vasculitic manifestations such as glomerulonephritis, purpura, and peripheral neuropathy. ANCA-negative disease is more often associated with eosinophilic tissue infiltration and cardiac involvement. These are tendencies, not rules: cardiac disease can occur with MPO positivity, and severe neuropathy or kidney disease can occur without detectable ANCA.
An MPO-positive result should not substitute for documenting eosinophilia. The complete blood count with differential and the absolute eosinophil count are central. An eosinophil count at or above 1.0 × 10⁹/L is heavily weighted in 2022 EGPA classification criteria, but diagnosis still requires a compatible clinical syndrome and exclusion of alternatives.
Important alternatives include severe eosinophilic asthma without vasculitis, allergic bronchopulmonary aspergillosis, parasitic infection, drug reactions, hypereosinophilic syndromes, eosinophilic leukemia, and other eosinophilic disorders. Exposure and travel history, medication review, IgE, parasite testing, hematologic studies, imaging, and tissue biopsy may be needed.
The antibody result cannot assess eosinophilic heart disease. Troponin, BNP or NT-proBNP, electrocardiography, echocardiography, and cardiac MRI are used according to symptoms and risk. Cardiac involvement may be clinically quiet at first and can be serious even when MPO-ANCA is negative.
The most accurate interpretation is phenotype-based: MPO-ANCA helps identify an ANCA-associated vasculitic component, while eosinophil counts and organ testing define the broader EGPA syndrome.
Non-Vasculitic and Drug-Related Positives
A positive MPO-ANCA should prompt a medication and infection review before it prompts a disease label. Several drugs can induce MPO-ANCA or an ANCA-associated vasculitic syndrome. Well-recognized examples include hydralazine and propylthiouracil. Methimazole, minocycline, levamisole-contaminated cocaine, and other exposures have also been reported.
Drug-induced disease can range from antibody positivity without organ injury to severe glomerulonephritis or pulmonary hemorrhage. Features may include very high MPO titers, positivity against several neutrophil antigens, ANA or anti-histone antibodies, and low complement, but no single pattern is universal. The latency may be months or years, so long-term medication use still matters.
Stopping the responsible drug is essential, but patients with organ-threatening disease may also require immunosuppression. The decision depends on kidney, lung, skin, or other injury rather than the antibody concentration alone.
Infection is another major pitfall. Infective endocarditis and other chronic infections can cause ANCA positivity, systemic inflammation, skin findings, and glomerulonephritis. Clues include fever, heart murmur, positive blood cultures, low complement, splenomegaly, embolic lesions, and immune-complex deposits on biopsy. Immunosuppression without antimicrobial treatment can be dangerous.
Other associations include inflammatory bowel disease, autoimmune hepatitis and primary sclerosing cholangitis, rheumatoid arthritis, systemic lupus erythematosus, and some malignancies. These conditions are more often linked to atypical ANCA patterns than strongly specific MPO results, but overlap occurs.
Laboratory error or interference should be considered when results conflict. ANA can complicate indirect immunofluorescence interpretation, while antigen-specific assays reduce that particular problem. Repeating a weak positive on a different high-quality platform may help, but repeated testing cannot replace evaluation of the patient.
Negative, Borderline, and Changing Results
A negative MPO-ANCA result means the assay did not detect antibody above its cutoff. It makes MPO-associated vasculitis less likely but does not exclude ANCA-associated disease. PR3-ANCA should be checked because some patients with MPA or EGPA have PR3 specificity, and some patients are negative for both.
A borderline result lies close to the decision threshold. Its meaning is especially sensitive to pretest probability, assay precision, and repeatability. Reasonable next steps may include confirming the result, reviewing p-ANCA or PR3 findings, checking for medication and infection causes, and focusing on objective organ evidence.
After treatment, MPO-ANCA often declines and may become negative. Persistent positivity does not necessarily mean persistent active disease. Some patients remain positive for years in clinical remission. Conversely, relapse can occur without a dramatic rise.
A return or rise in MPO-ANCA may precede relapse in some kidney-predominant patients and can justify closer observation. It should not automatically trigger rituximab, cyclophosphamide, or higher corticosteroid doses. Guidelines emphasize structured clinical follow-up because treatment escalation carries infection and toxicity risks.
Monitoring is most useful when the same assay is used and the antibody trend is interpreted beside:
- Urinalysis and urine microscopy
- Creatinine, eGFR, and urine protein
- Respiratory symptoms, oxygen level, and imaging
- Eosinophil count in EGPA
- Neurologic examination
- CRP, ESR, and blood count
- Treatment timing and B-cell counts where relevant
An antibody number is a risk signal, not a disease-activity score.
Frequency of repeat testing should match clinical need. Daily or weekly MPO measurements add little during most hospitalizations because organ trends change management faster. During stable remission, routine intervals vary by specialist and relapse history. Testing is most defensible when a result would change the intensity of observation, prompt urine or imaging reassessment, or clarify new symptoms—not simply because a calendar date has arrived.
Next Tests and Urgent Warning Signs
When MPO-ANCA is positive, immediate next tests should be driven by symptoms but usually include a complete blood count with differential, creatinine, eGFR, electrolytes, urinalysis, urine microscopy, and quantitative urine protein. CRP and ESR help establish inflammatory context. Complement, ANA, anti-double-stranded DNA, anti-GBM antibody, cultures, and viral testing may be added to evaluate mimics.
Chest symptoms require pulse oximetry and imaging. Unexplained anemia plus new lung opacities should raise concern for alveolar hemorrhage even without hemoptysis. Asthma and eosinophilia call for sinus and lung assessment and, in EGPA, deliberate cardiac and neurologic screening.
Kidney, skin, nerve, or lung biopsy may provide confirmation. Kidney biopsy is especially valuable because it distinguishes pauci-immune glomerulonephritis from immune-complex and anti-GBM disease and estimates chronic damage. Treatment should not await biopsy when a rapidly progressive, clinically convincing pulmonary-kidney syndrome threatens life or organ function.
Emergency evaluation is needed for coughing blood, severe breathlessness, low oxygen, chest pain, rapidly reduced urine output, marked swelling, confusion, severe weakness, or quickly worsening kidney tests. New foot or wrist drop, severe abdominal pain, black or bloody stool, or sudden visual symptoms also requires prompt care.
For an isolated positive result without objective organ findings, the appropriate response is measured rather than dismissive or alarmist. Confirm the clinical reason for testing, review drugs and infections, perform basic kidney and blood screening, and arrange specialist interpretation when the result is clearly positive or symptoms are compatible. The diagnosis is made from the whole pattern—not from MPO-ANCA alone.
References
- Current Diagnosis and Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. 2025. Peer-reviewed review.
- Clinical Value at Baseline and Follow-Up of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibodies in ANCA-Associated Vasculitis. 2025. Peer-reviewed cohort study.
- Drug-Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Features, Diagnosis, and Treatment. 2025. Peer-reviewed review.
- ANCA-MPO: Is This a Useful Test?. 2023. Peer-reviewed diagnostic study.
- 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. 2022. Validated classification criteria.
- EULAR Recommendations for the Management of ANCA-Associated Vasculitis: 2022 Update. 2024. International recommendations.
Disclaimer
This article is for education and does not replace medical diagnosis or treatment. MPO-ANCA results must be interpreted with symptoms, medication and infection history, urine, kidney function, eosinophils, imaging, and biopsy. Seek emergency care for coughing blood, low oxygen, severe breathlessness, rapidly reduced urine, major swelling, confusion, chest pain, or rapidly progressive weakness.
